Qirui Group Makes Its Debut at CPHI China 2024

From June 19 to 21, 2024, the 22nd CPHI China and the 17th PMEC China—the world’s leading trade shows for pharmaceutical ingredients and pharmaceutical machinery, packaging equipment, and materials—grandly opened at the Shanghai New International Expo Center.

As the annual highlight of the pharmaceutical industry, this exhibition is not only unprecedented in scale but also draws extensive attention from exhibitors, visitors, and the media worldwide. More than 3,400 domestic and international companies are participating, bringing together pharmaceutical firms and industry experts from home and abroad to showcase cutting-edge innovative products, explore opportunities for industry development, and expand avenues for international cooperation. Qirui Group has been invited to exhibit at the event.

At CPHI China 2024, the Group’s subsidiaries—Wuhan Qirui Pharmaceutical Co., Ltd., Wuhan Ruisheng Pharmaceutical Co., Ltd., and Shandong Ruiyin Bioengineering Co., Ltd.—jointly showcased Qirui Group’s outstanding technological innovation capabilities and robust research strength in the fields of active pharmaceutical ingredients and pharmaceutical intermediates to a global audience.

During the exhibition, Ruisheng Pharmaceutical, Qirui Pharmaceutical, and Ruiyin Biotechnology leveraged their outstanding technological strengths and diversified product portfolios to attract numerous experts from domestic and international pharmaceutical companies, as well as both new and existing clients, who stopped by for discussions. Members of the Qirui team provided visitors with comprehensive product presentations, technical consultations, tailored recommendations, and collaborative partnership proposals, highlighting the group’s robust R&D and manufacturing capabilities in areas such as bioenzyme synthesis, advanced chemical synthesis, custom intermediate production, and new-product development. They also shared the company’s long-term strategic plans, including global regulatory registration strategies, marketing and market deployment initiatives, and new-project development roadmaps, earning widespread acclaim from partners and customers at home and abroad.

Throughout its history, Qirui Group has upheld the core values of “quality and responsibility,” pursued a path of innovative R&D and internationalization, continuously increased R&D investment, enhanced product quality, engaged in global competition, and delivered high-quality, specialized products and services to patients worldwide. Looking ahead, the company will actively expand into international markets, strengthen collaboration with renowned domestic and international enterprises, and jointly promote the healthy development of the pharmaceutical industry.